UROKINASE AS AN ATNICOAGULANT FOR LEFT VENTRICULAR ASSIST DEVICE (LVAD)

Abstract

To evaluate the fibrinolysis therapy using urokinase as an anticoagulant for LVAD, coagulative study was made comparing with protease inhibitor (nafamostat mesilate).
U rokinase administration as a sole anticoagulant causes marked fibrinogen decrease and significant α₂-plasmin inhibitor decrease. It is considered that urokinase cannot prevent the activation of the blood coagulation system. So sole administration of urokinase is not an appropreate anticoagulation therapy for LVAD. Some conbination therapy is desirable for urokinase.